OpenAI’s Miles Wang targets $2B valuation for new AI drug discovery startup

On July 14, 2026 (July 15 UTC), TechCrunch reported that OpenAI researcher Miles Wang is leaving to found an AI drug discovery startup and is in talks to raise about $200 million at a $2 billion valuation, with Lightspeed Venture Partners in discussions to lead. Wang publicly disputed those specific funding figures but did not provide alternatives.